Abstract: The invention is directed to LDCAM as a purified and isolated protein, the DNA encoding the LDCAM, host cells transfected with cDNAs encoding LDCAM, processes for preparing LDCAM polypeptides and compositions and methods for treating utilizing LDCAM polypeptides.

Abstract: The present invention provides amino acid sequences of polypeptides that are encoded by genes within the human genome, the Ras-like protein polypeptides of the present invention. The present invention specifically provides isolated polypeptide and nucleic acid molecules, methods of identifying orthologs and paralogs of the Ras-like protein polypeptides, and methods of identifying modulators of the Ras-like protein polypeptides.

Abstract: The invention relates to compositions and methods for assaying or detecting “Apolipoprotein AIV-related protein” (AA4RP) in samples. In particular, it relates to a method allowing the direct measurement of AA4RP in biological samples. The invention also relates to synthetic products of AA4RP, the corresponding antibodies and the kits containing them, and their uses for the detection, quantification of AA4RP in a sample, or yet the quantification of atherogenic and non-atherogenic lipoparticles in a sample.

Abstract: The present invention relates to polypeptides having cellobiohydrolase I activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.

Abstract: Novel human polunucleotide and polypeptide sequences are disclosed that can be used in therapeuutic, diagnostic, and pharmacogenomic applications.

Abstract: The invention relates to an isolated nucleic acid molecule encoding a caspase-14 polypeptide or functional fragment thereof, a vector that contains the nucleic acid molecule and a host cell that contains the vector. The invention also relates to an isolated gene encoding caspase-14, as well as functional fragments thereof. The gene or nucleic acid molecule can include single or double stranded nucleic acids corresponding to coding or non-coding strands of the caspase-14 nucleotide sequence. Isolated caspase-14 polypeptides or functional fragments thereof are also provided, as are antibodies that specifically bind thereto. In addition, the invention relates to methods of identifying compounds that modulate caspase-14 activity.

Abstract: The present invention relates to a novel polypeptide encoding a protein which is the full length human ortholog of E3&agr; ubiquitin ligase. The invention also relates to vector, host cells, antibodies and recombinant methods for producing the polypeptide. In addition, the invention discloses therapeutic, diagnostic and research utilities for these and related products.

Abstract: The invention provides isolated nucleic acids molecules, designated 46798 nucleic acid molecules, which encode a novel matrix metalloproteinase. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 46798 nucleic acid molecules, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a 46798 gene has been introduced or disrupted. The invention still further provides isolated 46798 proteins, fusion proteins, antigenic peptides and anti-46798 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

Abstract: The present invention describes a novel gene encoding a novel protein termed headpin (for head and neck serpin) that is homologous to known serine protease inhibitors. The invention describes methods and compositions of the nucleic acids, encoded proteins, antibodies, pharmaceuticals, cancer treatments, diagnostics and screens for modulators of headpin.

Abstract: The present invention provides amino acid sequences of polypeptides that are encoded by genes within the human genome, the Ras-like protein polypeptides of the present invention. The present invention specifically provides isolated polypeptide and nucleic acid molecules, methods of identifying orthologs and paralogs of the Ras-like protein polypeptides, and methods of identifying modulators of the Ras-like protein polypeptides.

Abstract: ERK-7 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing ERK-7 polypeptides and polynucleotides in diagnostic assays.

Abstract: The present invention concerns a method of identifying genetically modified mammalian cells using a mutated protein-tyrosine kinase receptor (PTKR) as a selectable marker in mammalian cells. Particularly preferred mutated PTKR selective markers are mutated epidermal growth factor receptor (EGFR) family members, and muscle specific tyrosine kinase receptor (MuSK-R) family members. Further a method for the immunoselection of transduced mammalian cells is disclosed comprising retrovirally transducing mammalian cells with a nucleic acid sequence encoding a mutated EGFR, incubating the transduced cells with a marked antibody which recognizes and binds specifically to the mutated PTKR, and identifying the marked transduced cells.

Abstract: The present invention provides a cDNA encoding a heretofore unknown enzyme termed heparanase II; constructs and recombinant host cells incorporating the cDNA; the heparanase II polypeptide encoded by the gene; antibodies to the polypeptide; and methods of making an using all of the foregoing.

Abstract: Reagents that regulate human protein kinase-like protein and reagents which bind to human protein kinase-like gene products can play a role in preventing, ameliorating, or correcting dysfunctions or diseases including, but not limited to, cancer, CNS disorders, COPD, obesity, diabetes, and cardiovascular disorders.

Abstract: The present invention solves the object of the present invention by providing a DNA encoding an L-ribose isomerase which isomerizes L-ribose into L-ribulose and vice versa, and the process for producing a polypeptide by recombinant DNA techniques using the DNA.

Abstract: Disclosed are human interleukin-1 &bgr; converting enzyme like apoptosis proteases-3 and 4 and DNA (RNA) encoding such polypeptides. Also provided is a procedure for producing such polypeptides by recombinant techniques and antibodies and antagonists against such polypeptides. Also provided are methods of using the polypeptides, for example, as an antitumor agent, and antiviral agent, and antibodies and antagonists against such polypeptides for example, for treating Alzheimer's disease, Parkinson's disease, rheumatoid arthritis and head injury. Diagnostic assays for identifying mutations in nucleic acid sequence encoding a polypeptide of the present invention and for detecting altered levels of the polypeptide of the present invention for detecting diseases are also disclosed.

Abstract: Isolated human monoclonal antibodies which bind to and inhibit human heparanase, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a transfectoma or in a nonhuman transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, nonhuman transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.

Abstract: Proteins having the activity of saccharose phosphate synthetase (SPS) and a process for obtaining the same.

Abstract: The present invention provides novel polynucleotides and proteins encoded by such polynucleotides, along with therapeutic, diagnostic and research utilities for these polynucleotides and proteins. In particular, the polypeptides and polynucleotides of the invention comprise amino acid and nucleic acid sequences of novel CD39-like gene and gene products.

Abstract: The invention concerns the genomic sequence and cDNA sequences of the PG-3 gene. The invention also concerns biallelic markers of the PG-3 gene. The invention also concerns polypeptides encoded by the PG-3 gene. The invention also deals with antibodies directed specifically against such polypeptides that are useful as diagnostic reagents.

Abstract: The present invention relates to newly identified polynucleotides, and polypeptides encoded by such polynucleotides, the use of such polypeptides, as well as the production of such polynucleotides and polypeptides. More particularly, a polypeptide of the present invention is a heparanase-related endoglucuronidase. The invention also relates to vectors and host cells comprising a polynucleotide of the invention. Furthermore, the invention relates to antibodies directed to polypeptides according to the present invention and to pharmaceutical compositions and diagnostic reagents comprising such antibodies, polypeptides or polynucleotides. The invention further relates to a method of altering, modifying or otherwise modulating the level of expression of the heparanase-related endoglucuronidase in a cell or in a organism. A further aspect of the invention are assay systems suitable for identifying modulators, e.g. agonists or antagonists of such polypeptides.

Abstract: The present invention provides a cDNA encoding a heretofore unknown polypeptide termed canine L-PBE; the canine L-PBE polypeptide encoded by the gene; antibodies to the polypeptide; and methods of making and using all of the foregoing.

Abstract: The present invention relates to nucleotide sequences of FHIT genes and amino acid sequences of their encoded proteins, as well as derivatives and analogs thereof, and antibodies thereto. The FHIT gene sequence is mutated in diseases involving cell overproliferation, particularly malignancies of the digestive tract. The present invention further relates to the use of FHIT genes and their encoded proteins as diagnostic and therapeutic reagents for the detection and treatment of disease states associated with cell overproliferation.

Abstract: The present disclosure provides attractin/mahogany-like polypeptides and fragments thereof, polynucleotides encoding such polypeptides and fragments, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides or fragments, and assays and methods employing these polypeptides, antibodies, and polynucleotides.

Abstract: The present invention relates to a novel polypeptide having a cell death inhibitory activity and use thereof, etc.

Abstract: The present invention relates to compositions and methods of treating and diagnosing disorders characterized the by the presence of antigens associated with inflammatory diseases and/or cancer, and nucleotide sequences, including expressed sequence tags (ESTs), oligonucleotide probes, polypeptides, vectors and host cells expressing such antigens PRO301, PRO362 or PRO245.

Abstract: A non-invasive method of testing for inflammatory bowel disease using a domain specific monoclonal antibody is described. A unique 18 residue amino acid sequence overexpressed in COX-2 has been identified for making and using the monoclonal antibody.

Abstract: The present invention provides cDNAs encoding deoxyribonuclease II&bgr; and isolated, purified deoxyribonuclease II&bgr; proteins. Antibodies against this protein and antisense agents targeted to a cDNA or corresponding mRNA encoding deoxyribonuclease II&bgr; are provided. In addition, methods of identifying and using modulators of deoxyribonuclease II&bgr; activity are described.

Abstract: The present invention provides a method of selecting or designing a compound for the ability to regulate JAK activity. The method comprises assessing the ability of the compound to modulate the interaction of the pseudo-substrate loop (PSL) with the kinase like domaain (KLD) of JAK. In addition the present invention provides compounds which inhibit JAK and methods of treatment of JAK-associated disease states.

Abstract: The present invention provides molecules including Pin2 and telomerase binding polypeptides, polynucleotides encoding such polypeptides, and antibodies specifically immunoreactive to said polypeptides. The invention also provides methods for screening agents which modulate the function or expression of said Pin2 and telomerase binding polypeptides. Methods are provided for disease diagnosis and treatment using said agents, said antibodies and oligonucleotides derived from the above polynucleotides.

Abstract: The present invention provides cDNAs encoding deoxyribonuclease II&bgr; and isolated, purified deoxyribonuclease II&bgr; proteins. Antibodies against this protein and antisense agents targeted to a cDNA or corresponding mRNA encoding deoxyribonuclease II&bgr; are provided. In addition, methods of identifying and using modulators of deoxyribonuclease II&bgr; activity are described.

Abstract: The present invention provides amino acid sequences of peptides that are encoded by genes within the human genome, the kinase peptides of the present invention. The present invention specifically provides isolated peptide and nucleic acid molecules, methods of identifying orthologs and paralogs of the kinase peptides, and methods of identifying modulators of the kinase peptides.

Abstract: The present invention provides a human apoptosis-associated protein (HAAP) and polynucleotides which identify and encode HAAP. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. In addition, the invention provides methods for producing HAAP and for treating or preventing disorders associated with expression of HAAP.

Abstract: The present invention relates to novel human glycosylation enzyme polypeptides and isolated nucleic acids containing the coding regions of the genes encoding such polypeptides. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human glycosylation enzyme polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human glycosylation enzyme polypeptides.

Abstract: The invention provides an antibody or antibody fragment specific to a domain of a GIT targeting agent, such as a polyclonal antibody, monoclonal antibody, chimeric antibody, single chain antibody, a Fab fragment or a Fab expression library. In particular, the invention provides an antibody or antibody fragment, wherein the GIT targeting agent is selected from the group consisting of ZElan033 (PAX2 15 mer), ZElan088 (HAX42-2 20 mer) or ZElan053 (P31 D-form 16 mer). Numerous methods using these GIT targeting agent specific antibodies are disclosed.

Abstract: The present invention is related to a method for producing antibody fragments. In particular, the invention involves a method for the production of F(ab′)2 fragments. The method comprises concentration of cell culture media and activation of endogenous enzymes present in the cell culture media by adjusting the temperature and pH.

Abstract: The invention provides purified ACT-4 receptor polypeptides, antibodies against these polypeptides and nucleic acids encoding ACT-4 receptor polypeptides. Also provided are methods of diagnosis and treatment using the same. ACT-4 receptors are preferentially expressed on the surface of activated CD4+ T-cells. ACT-4 receptors are usually expressed at low levels on the surface of activated CD8+ cells, and are usually substantially absent on resting T-cells, and on monocytes and B-cells (resting or activated). An exemplary ACT-4 receptor, termed ACT-4-h-1, has a signal sequence, an extracellular domain comprising three disulfide-bonded intrachain loops, a transmembrane domain, and an intracellular domain.

Abstract: The present invention provides polynucleotides and polypeptides of a human sphingosine-1-phosphate phosphatase, referred to herein as hSPP1. The polynucleotides and polypeptides are used to further provide expression vectors, host cells comprising the vectors, probes and primers, antibodies against the hSPP1 protein and polypeptides thereof, assays for the presence or expression of hSPP1 and assays for the identification of compounds that interact with hSPP1.

Abstract: Amino acid sequences and nucleotide sequences relating to aphid myrosinase are described. In a preferred aspect, the amino acid sequence comprises the sequence presented as SEQ ID No. 1.

Abstract: The present invention provides a novel all-trans-RA inducible all-trans-RA metabolizing cytochrome P450, P450RAI-2, that is predominantly expressed in the brain, cerebellum in particular. It is also expressed in normal and tumour lung tissue and in breast cancer cells and may have a correlation with lung and breast cancer. Human P450RAI-2 show 42% amino acid identity to human P450RAI-1 and when transfected into COS-1 cells causes the rapid conversion of all-trans-RA into more polar metabolites including the inactive products 4-oxo-RA, 4-OH-RA and 18-OH-RA. P450RAI-2, as with P450RAI-1, is also inducible in certain cultured cell lines exposed to all-trans-RA. Methods for and uses of the new polynucleotide, polypeptide, fragments thereof and inhibitors thereof, include the treatment of dermatological disorders, cancer and certain brain disorders.

Abstract: This application describes the cloning of p63, a gene at chromosome 3q27-29, that bears homology to the tumor suppressor p53. The p63 gene encodes at least six different isotypes. p63 was detected in a variety of human and mouse tissue and demonstrates remarkably divergent activities, such as the ability to transactivate p53 reporter genes and induce apoptosis. Isotopes of p63 lacking a transactivation domain act as dominant negatives towards the transactivation by p53 and p63.

Abstract: The invention concerns a method for early diagnosis of cancer in a patient which consists in identifying by any appropriate method the presence of autoantibodies directed against the Csk protein in a biological sample taken from said patient. The invention also concerns a kit for implementing said diagnostic method.

Abstract: The invention features novel RNase P molecules and nucleic acids encoding the same. Methods for discovery of antimicrobial compounds are also featured.

Abstract: Disclosed are compositions preferably for use in nucleic acid synthesis that include one or more anti-reverse transcriptase (RT) antibodies and/or one or more anti-DNA polymerase (DNAP) antibodies and/or single strand binding proteins (SSBs). Some of the disclosed compositions include one or more anti-DNAP antibodies and/or one or more anti-RT antibodies and one or more SSBs. Other disclosed compositions include two or more SSBs. The disclosed nucleic acid synthesis compositions also can include one or more DNAPs, one or more RTs, one or more nucleotides, one or more primers, and/or one or more templates.

Abstract: The invention provides a human Nek1-related protein kinase (NRPK) and polynucleotides which identify and encode NRPK. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating or preventing disorders associated with expression of NRPK.

Abstract: Amino acid sequences and nucleotide sequences relating to PDEXV are described. In a preferred aspect, the amino acid sequence comprises the sequence presented as SEQ ID NO:1.

Abstract: Human inositol monophosphatase H1 polynucleotide and DNA (RNA) encoding such polypeptides and a procedure for producing such polypeptide by recombinant techniques and utilizing such polypeptide for therapeutic purposes, for example, screening and designing compounds capable of inhibiting hIMP-H1 and mapping genetic diseases are disclosed. Further disclosed are antibodies against hIMP-H1 polypeptides and methods for producing such antibodies and utilizing such antibodies for therapeutic or diagnostic purposes. Also disclosed is antagonists against such polypeptide along with procedures for using such antagonists for therapeutic purposes, for example, for treating psychotic and depressive disorders. Diagnostic assays for identifying mutations in nucleic acid sequence encoding a polypeptide of the present invention and for detecting altered levels of the polypeptide of the present invention are also disclosed.

Abstract: This invention provides compositions, organisms and methodologies employing a novel human protein kinase, MCRK1. The novel human kinase has sequence homology to rat myotonic dystrophy kinase-related Cdc42 binding kinase (MRCK) alpha. The gene encoding the novel kinase is localized in locus 11q13 of human chromosome 11. The novel protein kinase comprises multiple functional/structural domains that include a kinase domain, a pkinase_C domain, a DAG-PE binding domain, and a CNH domain. The sequence and structure similarity between the novel human protein and rat MRCK alpha indicates that the novel human protein may function as a downstream effector of Cdc42 in cytoskeleton reorganization.

Abstract: The object of the present invention is to provide a polypeptide which can be used to produce a saccharide having a structure of cyclo{→6)-&agr;-D-glucopyranosyl-(1→3)-&agr;-D-glucopyranosyl-(1→6)-&agr;-D-glucopyranosyl-(1→3)-&agr;-D-glucopyranosyl-(1→}, a DNA encoding the polypeptide, and uses thereof.

Abstract: HUTUDO1 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods utilizing HUTUDO1 polypeptides and polynucleotides in diagnostic assays.